The evolution of the psoriatic lesion

British Journal of Dermatology

Volumn 157, Issue 1, 2007, Pages 4-15

  Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidermal proliferation; Immunology; Keratinization; Psoriasis

Indexed keywords

AMPHIREGULIN; ANTIPSORIASIS AGENT; BETA DEFENSIN 2; CALCITRIOL; CD1D ANTIGEN; CLOBETASOL PROPIONATE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; CORTICOSTEROID; CYCLOSPORIN; CYTOKERATIN 16; CYTOKERATIN 17; CYTOKERATIN 6; DEXAMETHASONE; EFALIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID BINDING PROTEIN; FIBRONECTIN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; KERATIN; KI 67 ANTIGEN; PSORIASIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

BLOOD ANALYSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG TARGETING; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; HISTOCOMPATIBILITY; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; NONHUMAN; NUDE MOUSE; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SCID MOUSE; SKIN DEFECT; SYMPTOMATOLOGY; XENOTRANSPLANTATION;

ANIMALS; CYTOKINES; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; PSORIASIS; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34250684883     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07907.x     Document Type: Review

References (100)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002 46 : 1 23.
2. Bos JD, Hagenaars C, Das PK et al. Predominance of 'memory' T cells (CD4+, CDw29+) over 'naïve' T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989 281 : 24 30.
3. Bovenschen HJ, van Vlijmen-Willems IMJJ, van de Kerkhof PCM, van Erp PEJ. Identification of lesional CD4+ CD25+ Foxp3+ regulatory T cells in psoriasis. Dermatology 2006 213 : 111 17.
4. Bovenschen HJ, Seyger MMB, van de Kerkhof PCM. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005 153 : 72 8.
5. Baker BS, Swain AD, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984 110 : 555 64.
6. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model. J Dermatol Sci 2000 24 : 212 25.
7. Cameron AL, Kirby B, Frei W, Griffiths CEM. Natural killer and natural killer T-cells in psoriasis. Arch Dermatol Res 2002 294 : 363 9.
8. Bonish B, Jullien D, Dutronc Y. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-γ production by NK-T-cells. J Immunol 2000 165 : 4076 85.
9. Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue CD4+ CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005 174 : 164 73.
10. Nickoloff BJ, Griffiths CEM. Lymphocyte trafficking in psoriasis: a new perspective emphasizing the dermal dendrocyte with active dermal recruitment mediated via endothelial cells followed by intra-epidermal T-cell activation. J Invest Dermatol 1990 95 : S35 7.
11. Teunissen MBM. Langerhans cells and other skin dendritic cells. In : Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology (Bos JD, ed.), 3rd edn. Boca Raton, FL : CRC Press, 2005 123 82.
12. Prinz JC. Disease mimicry - a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry Autoimmun Rev 2004 3 : 10 15.
13. Bos JD, de Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005 152 : 1098 107.
14. Rogalski C, Meyer-Hoffert E, Proksch E, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo. J Invest Dermatol 2002 118 : 49 54.
15. van den Oord JJ, de Wolf-Peeters C. Epithelium-lining macrophages in psoriasis. Br J Dermatol 1994 130 : 589 94.
16. Smith CH, Barker JN. Pathogenic aspects of psoriasis: cell trafficking and role of adhesion molecules in psoriasis. In : Pathogenic Aspects of Psoriasis (de Kerkhof PCM, Bos JD, eds). New York : Elsevier, 1995 151 60.
17. Priestly GC, Adams LW. Hyperactivity of fibroblasts cultured from psoriatic skin. I. Faster proliferation and effect of serum withdrawal. Br J Dermatol 1983 109 : 149 56.
18. MacKie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol 1988 107 : 2757 67.
19. van Erp PEJ, de Mare S, Rijzewijk JJ et al. A sequential double immunoenzymic staining procedure to obtain cell kinetic information in normal and hyperproliferative epidermis. Histochem J 1989 21 : 343 7.
20. Castelijns FACM, Gerritsen MJP, van Erp PEJ, van de Kerkhof PCM. Cell kinetic evidence for increased recruitment of cycling epidermal cells in psoriasis: ratio of histone and Ki-67 antigen expression is constant. Dermatology 2000 200 : 25 30.
21. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal stem, keratinocytes. J Clin Invest 1995 95 : 317 27.
22. Pasch MC, Timar KK, van Meurs M et al. In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol 2004 203 : 839 48.
23. Pasch MC, Bos JD, Asghar SS. Activation of complement in psoriasis. Clin Exp Dermatol 1998 23 : 189 90.
24. de Jong EMGJ, van Vlijmen IM, van Erp PEJ. Keratin 17: a useful marker in anti-psoriatic therapies. Arch Dermatol Res 1991 283 : 480 2.
25. Schalkwijk J, Chang A, Janssen P et al. Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermis. Br J Dermatol 1990 122 : 631 41.
26. Siegenthaler G, Hotz R, Chatellard-Gruaz D et al. Characterization and expression of a novel human fatty acid-binding protein: the epidermal type (E-FABP). Biochem Biophys Res Commun 1993 190 : 482 7.
27. Madsen P, Rasmussen HH, Leffers H et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein 'psoriasin' that is highly upregulated in psoriatic skin. J Invest Dermatol 1991 97 : 701 12.
28. Elder JT, Fisher GJ, Lindquist PB et al. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989 243 : 811 14.
29. Cook PW, Pittelkow MR, Keeble WW et al. Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 1992 52 : 3224 7.
30. Nanney LB, Yates RA, King LE Jr. Modulation of epidermal growth factor receptors in psoriatic lesions during treatment with topical EGF. J Invest Dermatol 1992 98 : 296 301.
31. Hammerberg C, Arend EP, Fisher GJ et al. Interleukin-1 receptor antagonist in normal and psoriatic epidermis. J Clin Invest 1992 90 : 571 83.
32. Schmid P, Cox D, McMaster GK, Itin P. In situ hybridization analysis of cytokine, proto-oncogene and tumor suppressor gene expression in psoriasis. Arch Dermatol 1993 285 : 334 40.
33. Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991 138 : 129 40.
34. Tettlebach W, Nanney L, Ellis D et al. Localization of MGSA/GRO protein in cutaneous lesions. J Cutan Pathol 1993 20 : 259 66.
35. Bernard BA, Asselineau D, Schaftar D, Darmon MY. Abnormal sequence of expression of differentiation markers in psoriatic epidermis: inversion of two steps in the differentiation program J Invest Dermatol 1988 90 : 801 5.
36. Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'type 1' inflammatory gene expression. Trends Immunol 2004 25 : 295 305.
37. Chang EY, Hammerberg C, Fisher G et al. T-cell activation is potentiated by cytokines released by lesional psoriatic but not normal epidermis. Arch Dermatol 1992 128 : 1479 85.
38. Baker BS, Ovigne JM, Powles AV et al. Normal keratinocytes express toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003 148 : 670 9.
39. Curry JL, Quin JZ, Bonish B et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003 127 : 178 86.
40. Steinert PM. The complexity and redundancy of epithelial barrier function. J Cell Biol 2000 151 : F5 8.
41. Placek W, Haftek M, Thivolet J. Sequence of changes in psoriatic epidermis. Immunocompetent cell redistribution precedes altered expression of keratinocyte differentiation markers. Acta Derm Venereol (Stockh) 1988 68 : 369 77.
42. Prens EP, Benne K, van Joost T, Benner R. The autologous mixed epidermal cell-T lymphocyte reaction is elevated in psoriasis: a crucial role for epidermal HLA-DR+/CD1a- antigen-presenting cells. J Invest Dermatol 1991 96 : 880 7.
43. Zhou X, Krueger JG, Kao M-CJ et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003 13 : 69 78.
44. Cooper KD, Baadsbaard O, Ellis CN et al. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 1990 94 : 649 56.
45. Heng MC, Allen SG, Chase DG. High endothelial venules in involved and uninvolved psoriatic skin: recognition by homing receptors on cytotoxic T lymphocytes. Br J Dermatol 1988 118 : 315 26.
46. Kemeny L, Csato M, Nyiradi J et al. Decreased capillary resistance of the uninvolved skin in psoriasis. Acta Derm Venereol (Stockh) 1988 68 : 459 60.
47. Rulo HF, Westphal JR, van de Kerkhof PCM et al. Expression of endoglin in psoriatic involved and uninvolved skin. J Dermatol Sci 1995 10 : 103 9.
48. Priestley GC. The fibroblast in psoriasis: master or slave Eur J Dermatol 1991 1 : 185 91.
49. Körver JEM, van Dijnhoven MWFM, Pasch MC et al. Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis. Br J Dermatol 2006 155 : 688 94.
50. van de Kerkhof PCM. Pathogenesis. In : Textbook of Psoriasis (van de Kerkhof PCM, ed.), 2nd edn. Oxford : Blackwell Publications, 2003 124 9.
51. DePita O, Ruffelli M, Cadoni S et al. Psoriasis: comparison of immunological markers in patients with acute and remission phase. J Dermatol Sci 1996 13 : 118 24.
52. Koreck A, Suranyi A, Szony BJ et al. CD3(+) CD56(+) NK T cells are significantly decreased in the peripheral blood of patients with psoriasis. Clin Exp Immunol 2002 127 : 176 82.
53. Lecewicz-Torún B, Pietrzak A, Rolinski J, Brzozowski W. The peripheral blood lymphocyte pattern in psoriasis preceded by an infection. Med Sci Monit 2001 7 : 889 93.
54. van der Vliet HJJ, von Blomberg BME, Nishi N et al. Circulating Vα24+ Vβ11+ NKT-cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001 100 : 144 8.
55. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004 150 : 917 28.
56. Brown WR, Hardy MH. Effects of topical triamcinolone acetonide, retinoic acid and anthralin on asebia mouse skin. J Invest Dermatol 1984 82 : 412 16.
57. Hogenesch H, Gijbels MJJ, Zurcher C. The chronic proliferative dermatitis (cpd) mutation chromosome? In : Handbook of Mouse Mutations with Skin, Hair Abnormalities. Animal Models. Bio Medical Tools (Sundberg JP, ed.). Boca Raton, FL : CRC Press, 1994 217 20.
58. Sunberg JP, Boggess D, Shultz LD, Beamer WG. The flaky skin (fsn) mutation chromosome? In : Handbook of Mouse Mutations with Skin, Hair Abnormalities. Animal Models. Bio Medical Tools (Sundberg JP, ed.). Boca Raton, FL : CRC Press, 1994 253 68.
59. Groves RW, Mizutani H, Kieffer JD, Kupper TS. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1α in basal epidermis. Proc Natl Acad Sci USA 1995 92 : 11874 8.
60. Carroll JM, Crompton T, Seery JP, Watt FM. Transgenic mice expressing IFN-γ in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 1997 108 : 412 22.
61. Turksen K, Kupper T, Degenstein L et al. Interleukin 6: insights to its function by overexpression in transgenic mice. Proc Natl Acad Sci USA 1992 89 : 5068 72.
62. Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF-α during epidermal development and differentiation. Genes Dev 1991 5 : 714 27.
63. Guo L, Yu QC, Fuchs E. Targeting expression of keratinocyte growth factor to keratinocytes elicits striking changes in epithelial differentiation in transgenic mice. EMBO J 1993 12 : 973 86.
64. Blessing M, Schirmacher P, Kaiser S. Overexpression of bone morphogenic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions. J Cell Biol 1996 135 : 227 39.
65. Xia YP, Li B, Hylton D et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003 102 : 161 8.
66. Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001 104 : 9 19.
67. Cook PW, Piepkorn M, Clegg CH et al. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 1997 100 : 2286 94.
68. Bullard DC, Scharfetter-Kochanek K, McArthur MJ et al. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc Natl Acad Sci USA 1996 93 : 2116 21.
69. Kess D, Peters T, Zamek J et al. CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J Immunol 2003 171 : 5697 706.
70. Carroll JM, Romero MR, Watt FM. Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis. Cell 1995 83 : 957 68.
71. Schön MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med 1997 3 : 183 8.
72. Nickoloff BJ, Kunkel SL, Burdick M, Stricker RM. Severe combined immunodeficient mouse and human psoriatic skin chimeras - validation of a new model. Am J Pathol 1995 146 : 580 8.
73. Gilhar A, David M, Ulmann Y et al. Lymphocyte dependence of psoriatic pathology in human psoriatic skin engrafted to SCID mouse. J Invest Dermatol 1997 109 : 283 9.
74. Sugai S, Iizuka M, Kawakubo Y et al. Histological and immunochemical studies of the human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci 1998 17 : 85 92.
75. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996 98 : 1878 87.
76. Nickoloff BJ, Wrone-Smith T. Injection of prepsoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999 155 : 145 58.
77. Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. Response of murine and normal human skin to injection of allogenic blood derived psoriatic immunocytes: detection of T-cells expressing receptors typically present on natural killer cells, including CD94, CD158 and CD161. Arch Dermatol 1999 135 : 546 52.
78. Boehncke WH, Zollner TM, Dressel D, Kaufmann R. Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogenic transplantation model. J Cutan Pathol 1997 24 : 1 7.
79. Boehncke WH, Kock M, Hardt-Weinelt K et al. The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs. Arch Dermatol 1999 291 : 104 6.
80. Dam TN, Kang S, Nickoloff BJ, Voorhees JJ. 1α,25- dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 1999 113 : 1082 9.
81. Zeigler M, Chi Y, Tumas DB et al. Anti-CD11a ameliorates disease in the human psoriatic skin SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab Invest 2001 81 : 1253 61.
82. Dam TS, Kang S, Nickoloff BJ. Pharmacological modulation of induction and treatment of psoriasis using human skin grafted onto SCID mice. J Invest Dermatol 1997 108 : 572.
83. Boyman O, Hefti HP, Conrad C et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J Exp Med 2004 199 : 731 6.
84. Nestle FO, Conrad C, Tun-Kyi A et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005 202 : 135 43.
85. Gilliet M, Conrad C, Geiges M et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004 140 : 1490 5.
86. Boyman O, Conrad C, Dudli C et al. Activation of dendritic antigen-presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br J Dermatol 2005 152 : 1095 7.
87. Sano S, Chan KS, Carbajal S et al. Stat3 links activated keratinocytes and immunocytes required for the development of psoriasis in a novel transgenic mouse model. Nat Med 2004 11 : 43 9.
88. Zenz R, Eferl R, Kenner L et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005 437 : 369 75.
89. Pasparakis M, Courtois G, Hafner M et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific delation of IKK2. Nature 2002 417 : 861 6.
90. Stratis A, Pasparakis M, Rupec RA et al. Pathogenetic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006 116 : 2094 103.
91. Eyre RW, Krueger GP. Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity Koebner reactions. Br J Dermatol 1982 106 : 153 9.
92. Gerritsen MJP, van Erp PEJ, van Vlijmen-Willems IMJJ et al. Repeated tape stripping of normal human skin: a histological assessment and comparison with events seen in psoriasis. Arch Dermatol Res 1994 256 : 455 61.
93. Chang A, de Jong GJ, Mier PD, van de Kerkhof PCM. Enzymatic quantification of polymorphonuclear leukocytes in normal and psoriatic skin following standardized injury. Clin Exp Dermatol 1978 13 : 62 6.
94. van de Kerkhof PCM, van Rennes H, de Grood RM et al. Responses of the clinically uninvolved skin of psoriatics to standardized injury. Br J Dermatol 1983 109 : 287 94.
95. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 1985 277 : 352 8.
96. Gillitzer R, Wolff K, Tong D et al. MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol 1993 101 : 127 31.
97. Glade CP, van Erp PEJ, Werner-Schlenzka H, van de Kerkhof PCM. A clinical and flow cytometric model to study remission and relapse in psoriasis. Acta Derm Venererol (Stockh) 1998 78 : 180 5.
98. Castelijns FACM, Gerritsen MJP, van Vlijmen-Willems IMJJ et al. The epidermal phenotype during initiation of the psoriatic lesion in the symptomless margin of relapsing psoriasis. J Am Acad Dermatol 1999 40 : 901 9.
99. van de Kerkhof PCM, Gerritsen MJP, de Jong EMGJ. Transition from symptomless to lesional psoriatic skin. Clin Exp Dermatol 1996 21 : 325 9.
100. Hull SM, Goodfield M, Wood EJ, Cunliffe WJ. Active and inactive edges of psoriatic plaques: identification by tracing and investigation by laser-Doppler flowmetry and immunohistology. J Invest Dermatol 1989 92 : 782 5.